Literature DB >> 2204443

The possible role of electron-transfer complexes in the antitumour action of amsacrine analogues.

B C Baguley1.   

Abstract

Amsacrine is a DNA intercalating agent which is active against a number of tumours in mice and is used for the treatment of leukaemia in humans. In its DNA-bound form, amsacrine efficiently quenches the fluorescence of ethidium. Fluorescence lifetime studies demonstrate two populations of DNA-bound ethidium. The first, whose fluorescence lifetime is constant at approx. 3 ns and whose proportion increases with increasing amsacrine binding ratio, may comprise molecules bound in close proximity to amsacrine. The second, whose fluorescence lifetime is longer and variable (10-24 ns) and whose proportion decreases with increasing amsacrine binding ratio, may comprise molecules three or more base-pairs away from ethidium. Studies with a number of derivatives of 9-anilinoacridine containing different anilino substituents suggest that the observed wide variation in quenching capacity is correlated with the magnitude of the substituent dipole moment in a particular direction. Consideration of the geometry of the DNA-binding complex indicates that the negative pole of a dipole established in the anilino ring is directed towards a positively charged site on the ethidium molecule. Quenching of ethidium fluorescence may therefore occur where an electron-transfer complex has formed between ethidium and amsacrine molecules. To ascertain whether electron-transfer complex formation is biologically important in the amsacrine series, ethidium quenching has been quantitated and compared with activity against a transplantable neoplasm in mice, the Lewis lung carcinoma. Compounds which strongly quench ethidium fluorescence are in general highly active antitumour agents. The results are discussed in terms of a model where amsacrine has both a DNA-binding and a protein-binding domain, the latter possibly interacting by formation of an electron-transfer complex. The most likely protein-binding domain is on the enzyme topoisomerase II, the target for its cytotoxic activity.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2204443     DOI: 10.1016/0301-4622(90)80009-v

Source DB:  PubMed          Journal:  Biophys Chem        ISSN: 0301-4622            Impact factor:   2.352


  4 in total

1.  Optimization of Weight Ratio for DSPE-PEG/TPGS Hybrid Micelles to Improve Drug Retention and Tumor Penetration.

Authors:  Ya Jin; Zimei Wu; Caibin Li; Weisai Zhou; John P Shaw; Bruce C Baguley; Jianping Liu; Wenli Zhang
Journal:  Pharm Res       Date:  2018-01-04       Impact factor: 4.200

2.  Femtosecond dynamics of the DNA intercalator ethidium and electron transfer with mononucleotides in water.

Authors:  T Fiebig; C Wan; S O Kelley; J K Barton; A H Zewail
Journal:  Proc Natl Acad Sci U S A       Date:  1999-02-16       Impact factor: 11.205

3.  Cytokinetic differences in the action of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide as compared with that of amsacrine and doxorubicin.

Authors:  A Haldane; K M Holdaway; G J Finlay; B C Baguley
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

4.  Multiseed liposomal drug delivery system using micelle gradient as driving force to improve amphiphilic drug retention and its anti-tumor efficacy.

Authors:  Wenli Zhang; Caibin Li; Ya Jin; Xinyue Liu; Zhiyu Wang; John P Shaw; Bruce C Baguley; Zimei Wu; Jianping Liu
Journal:  Drug Deliv       Date:  2018-11       Impact factor: 6.419

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.